Pilot study of a pegfilgrastim injection as an inducer to mobilize CD34 positive stem cells into the peripheral blood
Not Applicable
- Conditions
- Malignant Lymphoma
- Registration Number
- JPRN-UMIN000020853
- Lead Sponsor
- Hokkaido University Hospital
- Brief Summary
Our data indicated that 3.6mg pegfilgrastim on day 7 can efficiently mobilize CD34+ cells to peripheral blood without any severe adverse events.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
1 Patients must not have any allergy with pegfilgrastim or filgrastim in the past 2 Pregnant or nursing women 3 SpO2 less than 94%: room air 4 Cardiac dysfunction: LVEF<50% 5 Liver dysfunction, Renal dysfunction ALT more than 5*ULN T.Bil more than 5*ULN sCr more than 2*ULN 6 HIV1/2 infection 7 Uncontrolled mental disease 8 Uncontrolled hypertension 9 Uncontrolled diabetes 10 Uncontrolled infectious disease 11 Dual malignancy 12 Patients were judged unqualified for this study by attending physician
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Actual number of CD34 positive stem cells after pegfilgrastim injection
- Secondary Outcome Measures
Name Time Method